Need help finding what you are looking for?
Contact Us
PUBLISHER: GlobalData | PRODUCT CODE: 1271077
PUBLISHER: GlobalData | PRODUCT CODE: 1271077
Bioabsorbable Stents (BAS) Pipeline Report Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update
PUBLISHED:
PAGES: 111 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Abstract
GlobalData's Medical Devices sector report, "Bioabsorbable Stents (BAS) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" provides comprehensive information about the Bioabsorbable Stents (BAS) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Bioabsorbable stents are also known as bioreabsorbable or biodegradable coronary stents. The advantage of this stent is that it does not leave any metal body behind and hence, the possibility of late-stent thrombosis and restenosis decreases. Bioabsorbable stents help in better drug delivery compared to metallic stents.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Bioabsorbable Stents (BAS) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Bioabsorbable Stents (BAS) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Bioabsorbable Stents (BAS) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date
Product Code: GDME1519EPD
Table of Contents
1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
2 Introduction
- 2.1 Bioabsorbable Stents (BAS) Overview
3 Products under Development
- 3.1 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
- 3.2 Bioabsorbable Stents (BAS) - Pipeline Products by Territory
- 3.3 Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path
- 3.4 Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date
- 3.5 Bioabsorbable Stents (BAS) - Ongoing Clinical Trials
4 Bioabsorbable Stents (BAS) - Pipeline Products under Development by Companies
- 4.1 Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development
- 4.2 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
5 Bioabsorbable Stents (BAS) Companies and Product Overview
- 5.1 Abbott Vascular Inc Company Overview
- 5.1.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.2 Amaranth Medical Inc Company Overview
- 5.2.1 Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.3 Arterius Ltd Company Overview
- 5.3.1 Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.4 Biosensors International Group Ltd Company Overview
- 5.4.1 Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.5 Biosten, LLC Company Overview
- 5.5.1 Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview
- 5.6 Biotronik AG Company Overview
- 5.6.1 Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
- 5.7 Biotronik SE & Co KG Company Overview
- 5.7.1 Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
- 5.8 Biotyx Medical (Shenzhen) Co Ltd Company Overview
- 5.8.1 Biotyx Medical (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.9 Boston Scientific Corp Company Overview
- 5.9.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
- 5.10 Cardionovum GmbH Company Overview
- 5.10.1 Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
- 5.11 Cordis Corp Company Overview
- 5.11.1 Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
- 5.12 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview
- 5.12.1 HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
- 5.13 Icon Interventional Systems, Inc. Company Overview
- 5.13.1 Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
- 5.14 Japan Stent Technology Co., Ltd. Company Overview
- 5.14.1 Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
- 5.15 Kyoto Medical Planning Co Ltd Company Overview
- 5.15.1 Kyoto Medical Planning Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.16 Lifetech Scientific (Shenzhen) Co Ltd Company Overview
- 5.16.1 Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.17 Manli Cardiology Ltd Company Overview
- 5.17.1 Manli Cardiology Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.18 Meril Life Sciences Pvt Ltd Company Overview
- 5.18.1 Meril Life Sciences Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.19 Micell Technologies Inc Company Overview
- 5.19.1 Micell Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.20 Michigan Technological University Company Overview
- 5.20.1 Michigan Technological University Pipeline Products & Ongoing Clinical Trials Overview
- 5.21 MicroPort Scientific Corp Company Overview
- 5.21.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
- 5.22 Minvasys SAS Company Overview
- 5.22.1 Minvasys SAS Pipeline Products & Ongoing Clinical Trials Overview
- 5.23 MIV Therapeutics Inc Company Overview
- 5.23.1 MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.24 NanoCoeur, Inc. Company Overview
- 5.24.1 NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview
- 5.25 North Carolina State University Company Overview
- 5.25.1 North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview
- 5.26 Northwestern University Company Overview
- 5.26.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview
- 5.27 OrbusNeich Company Overview
- 5.27.1 OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview
- 5.28 Pediastent LLC Company Overview
- 5.28.1 Pediastent LLC Pipeline Products & Ongoing Clinical Trials Overview
- 5.29 QualiMed Innovative Medizinprodukte GmbH Company Overview
- 5.29.1 QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview
- 5.30 REVA Medical Inc Company Overview
- 5.30.1 REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.31 S3V Vascular Technologies Company Overview
- 5.31.1 S3V Vascular Technologies Pipeline Products & Ongoing Clinical Trials Overview
- 5.32 Shanghai Bio-heart Biological Technology Co Ltd Company Overview
- 5.32.1 Shanghai Bio-heart Biological Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.33 Shanghai Healing Medical Instruments Co Ltd Company Overview
- 5.33.1 Shanghai Healing Medical Instruments Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.34 Tepha Inc Company Overview
- 5.34.1 Tepha Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.35 Tremedics Medical Devices LLC Company Overview
- 5.35.1 Tremedics Medical Devices LLC Pipeline Products & Ongoing Clinical Trials Overview
- 5.36 UAB Minority Health and Health Equity Research Center Company Overview
- 5.36.1 UAB Minority Health and Health Equity Research Center Pipeline Products & Ongoing Clinical Trials Overview
- 5.37 University of Florida Company Overview
- 5.37.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview
- 5.38 University of Strathclyde Company Overview
- 5.38.1 University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview
- 5.39 VasoTech Inc. Company Overview
- 5.39.1 VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview
- 5.40 Xenogenics Corporation Company Overview
- 5.40.1 Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview
6 Bioabsorbable Stents (BAS)- Recent Developments
- 6.1 Mar 08, 2023: OrbusNeich Announces Record Revenue of US$136.8 Million, Adjusted Net Profit Up 25% to US$26.7 Million
- 6.2 Feb 09, 2023: Terumo Notice Concerning Revision of the Full-Year Financial Guidance for Fiscal Year Ending March 31, 2023
- 6.3 Feb 09, 2023: Terumo Corp Announces Consolidated Financial Results for the Third Quarter Ended December 31, 2022
- 6.4 Nov 10, 2022: Terumo Corp Announces Consolidated Financial Results for the Second Quarter Ended September 30, 2022
- 6.5 Aug 16, 2022: Boston Scientific Announces Upcoming Conference Schedule
- 6.6 Apr 28, 2022: Boston Scientific reports net sales of $3.03bn in Q1 2022
- 6.7 Apr 27, 2022: Boston Scientific Announces Results for First Quarter 2022
7 Appendix
- 7.1 Methodology
- 7.2 About GlobalData
- 7.3 Contact Us
- 7.4 Disclaimer
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.